192 related articles for article (PubMed ID: 35927410)
21. EQ-5D-5L Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M
Pharmacoeconomics; 2023 Nov; 41(11):1515-1524. PubMed ID: 37341959
[TBL] [Abstract][Full Text] [Related]
22. The EQ-5D-3L Valuation Study in Pakistan.
Malik M; Gu NY; Hussain A; Roudijk B; Purba FD
Pharmacoecon Open; 2023 Nov; 7(6):963-974. PubMed ID: 37702988
[TBL] [Abstract][Full Text] [Related]
23. Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' Protocol.
Yang F; Katumba KR; Roudijk B; Yang Z; Revill P; Griffin S; Ochanda PN; Lamorde M; Greco G; Seeley J; Sculpher M
Pharmacoeconomics; 2022 Mar; 40(3):309-321. PubMed ID: 34841471
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of EuroQol Valuation Technology (EQ-VT) Designs to Generate National Value Sets: Learnings from the Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study.
Jyani G; Yang Z; Sharma A; Goyal A; Stolk E; Purba FD; Grover S; Kaur M; Prinja S
Med Decis Making; 2023 Aug; 43(6):692-703. PubMed ID: 37480281
[TBL] [Abstract][Full Text] [Related]
25. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L.
Afshari S; Daroudi R; Goudarzi R; Mahboub-Ahari A; Yaseri M; Sari AA; Ameri H; Bahariniya S; Oliaei-Manesh A; Kalavani K; Zare Z; Hasannezhad E; Mirzaei M; Amiri Z
Qual Life Res; 2023 Jul; 32(7):2079-2087. PubMed ID: 36897530
[TBL] [Abstract][Full Text] [Related]
26. German Value Set for the EQ-5D-5L.
Ludwig K; Graf von der Schulenburg JM; Greiner W
Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
[TBL] [Abstract][Full Text] [Related]
27. EQ-5D-5L: a value set for Romania.
Olariu E; Mohammed W; Oluboyede Y; Caplescu R; Niculescu-Aron IG; Paveliu MS; Vale L
Eur J Health Econ; 2023 Apr; 24(3):399-412. PubMed ID: 35688994
[TBL] [Abstract][Full Text] [Related]
28. An EQ-5D-5L Value Set for Vietnam.
Mai VQ; Sun S; Minh HV; Luo N; Giang KB; Lindholm L; Sahlen KG
Qual Life Res; 2020 Jul; 29(7):1923-1933. PubMed ID: 32221805
[TBL] [Abstract][Full Text] [Related]
29. Estimating a social value set for EQ-5D-5L in Sweden.
Sun S; Chuang LH; Sahlén KG; Lindholm L; Norström F
Health Qual Life Outcomes; 2022 Dec; 20(1):167. PubMed ID: 36564844
[TBL] [Abstract][Full Text] [Related]
30. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
[TBL] [Abstract][Full Text] [Related]
31. A direct comparison between discrete choice with duration and composite time trade-off methods: do they produce similar results?
Roudijk B; Jonker MF; Bailey H; Pullenayegum E
Value Health; 2024 Jun; ():. PubMed ID: 38843979
[TBL] [Abstract][Full Text] [Related]
32. Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility study.
Chai Q; Yang Z; Liu X; An D; Du J; Ma X; Rand K; Wu B; Luo N
Eur J Health Econ; 2023 Oct; ():. PubMed ID: 37837519
[TBL] [Abstract][Full Text] [Related]
33. EQ-5D-5L Health-State Values for the Mexican Population.
Gutierrez-Delgado C; Galindo-Suárez RM; Cruz-Santiago C; Shah K; Papadimitropoulos M; Feng Y; Zamora B; Devlin N
Appl Health Econ Health Policy; 2021 Nov; 19(6):905-914. PubMed ID: 34173957
[TBL] [Abstract][Full Text] [Related]
34. Value Set for the EQ-5D-Y-3L in Hungary.
Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
[TBL] [Abstract][Full Text] [Related]
35. EQ-5D-5L Valuation for the Malaysian Population.
Shafie AA; Vasan Thakumar A; Lim CJ; Luo N; Rand-Hendriksen K; Md Yusof FA
Pharmacoeconomics; 2019 May; 37(5):715-725. PubMed ID: 30535779
[TBL] [Abstract][Full Text] [Related]
36. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
37. Estimating the EQ-5D-5L value set for the Philippines.
Miguel RTD; Rivera AS; Cheng KJG; Rand K; Purba FD; Luo N; Zarsuelo MA; Genuino-Marfori AJ; Florentino-Fariñas I; Guerrero AM; Lam HY
Qual Life Res; 2022 Sep; 31(9):2763-2774. PubMed ID: 35532835
[TBL] [Abstract][Full Text] [Related]
38. Valuation of the EQ-5D-5L in Taiwan.
Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
[TBL] [Abstract][Full Text] [Related]
39. EQ-5D-Y Value Set for Germany.
Kreimeier S; Mott D; Ludwig K; Greiner W;
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
[TBL] [Abstract][Full Text] [Related]
40. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values.
Karim S; Craig BM; Tejada RA; Augustovski F
Health Qual Life Outcomes; 2023 Jan; 21(1):1. PubMed ID: 36593473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
